AU2015237864B2 - Modified antibodies containing modified IgG2 domains which elicit agonist or antagonistic properties and use thereof - Google Patents

Modified antibodies containing modified IgG2 domains which elicit agonist or antagonistic properties and use thereof Download PDF

Info

Publication number
AU2015237864B2
AU2015237864B2 AU2015237864A AU2015237864A AU2015237864B2 AU 2015237864 B2 AU2015237864 B2 AU 2015237864B2 AU 2015237864 A AU2015237864 A AU 2015237864A AU 2015237864 A AU2015237864 A AU 2015237864A AU 2015237864 B2 AU2015237864 B2 AU 2015237864B2
Authority
AU
Australia
Prior art keywords
antibody
modified
modified antibody
cells
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015237864A
Other languages
English (en)
Other versions
AU2015237864A1 (en
Inventor
Martin J. Glennie
Ann White
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
Original Assignee
Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201405264A external-priority patent/GB201405264D0/en
Priority claimed from GB201405275A external-priority patent/GB201405275D0/en
Application filed by Cancer Research Technology Ltd filed Critical Cancer Research Technology Ltd
Publication of AU2015237864A1 publication Critical patent/AU2015237864A1/en
Assigned to CANCER RESEARCH TECHNOLOGY LIMITED reassignment CANCER RESEARCH TECHNOLOGY LIMITED Request for Assignment Assignors: UNIVERSITY OF SOUTHAMPTON
Application granted granted Critical
Publication of AU2015237864B2 publication Critical patent/AU2015237864B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C07K16/242—Lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2015237864A 2014-03-24 2015-03-24 Modified antibodies containing modified IgG2 domains which elicit agonist or antagonistic properties and use thereof Ceased AU2015237864B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1405264.1 2014-03-24
GB201405264A GB201405264D0 (en) 2014-03-24 2014-03-24 Modified antibodies containing lgG2 Domains which possess agonist or antagonistic properties and therapeutic use thereof
GB201405275A GB201405275D0 (en) 2014-03-25 2014-03-25 Modified antibodies containing lgG2 Domains which possess agonist or antagonistic properties and therapeutic use thereof
GB1405275.7 2014-03-25
PCT/IB2015/052166 WO2015145360A1 (en) 2014-03-24 2015-03-24 Modified antibodies containing modified igg2 domains which elicit agonist or antagonistic properties and use thereof

Publications (2)

Publication Number Publication Date
AU2015237864A1 AU2015237864A1 (en) 2016-10-13
AU2015237864B2 true AU2015237864B2 (en) 2020-12-03

Family

ID=52829255

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015237864A Ceased AU2015237864B2 (en) 2014-03-24 2015-03-24 Modified antibodies containing modified IgG2 domains which elicit agonist or antagonistic properties and use thereof

Country Status (7)

Country Link
US (2) US11059898B2 (enExample)
EP (2) EP3122779B1 (enExample)
JP (2) JP6682498B2 (enExample)
CN (2) CN113912723A (enExample)
AU (1) AU2015237864B2 (enExample)
CA (1) CA2943167A1 (enExample)
WO (1) WO2015145360A1 (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI677507B (zh) 2012-06-22 2019-11-21 達特茅斯學院基金會 新穎之ｖｉｓｔａ－ｉｇ構築體及ｖｉｓｔａ－ｉｇ用於治療自體免疫、過敏及發炎病症之用途
EP2953634B1 (en) 2013-02-07 2021-05-26 The General Hospital Corporation Methods for expansion or depletion of t-regulatory cells
HRP20210122T1 (hr) 2013-05-02 2021-04-16 Anaptysbio, Inc. Protutijela usmjerena protiv programirane smrti-1 (pd-1)
SMT202100116T1 (it) 2014-05-28 2021-05-07 Agenus Inc Anticorpi anti-gitr e metodi di utilizzo degli stessi
DK3151921T3 (da) 2014-06-06 2019-12-02 Bristol Myers Squibb Co Antistoffer mod glucocorticoid-induceret tumornekrosefaktor- receptorer (gitr) og anvendelser deraf
DK3221363T3 (da) 2014-11-21 2020-08-10 Bristol Myers Squibb Co Antistoffer mod cd73 og anvendelser deraf
HRP20201756T8 (hr) * 2014-11-21 2021-08-20 Bristol-Myers Squibb Company Antitijela koja sadrže modificirane regije teškog lanca
US10689449B2 (en) 2015-01-20 2020-06-23 Igm Biosciences, Inc. Multimeric death domain-containing receptor-5 (DR5) antibodies and uses thereof
ES2962885T3 (es) 2015-05-15 2024-03-21 Massachusetts Gen Hospital Anticuerpos antagonistas de la superfamilia del receptor del factor de necrosis tumoral
CN111234027A (zh) 2015-05-21 2020-06-05 哈普恩治疗公司 三特异性结合蛋白质及使用方法
CN107743586B (zh) 2015-06-03 2021-07-02 百时美施贵宝公司 用于癌症诊断的抗gitr抗体
MX395257B (es) 2015-06-29 2025-03-25 Bristol Myers Squibb Co Anticuerpos para cd40.
EP3340999A4 (en) 2015-08-28 2019-06-12 The General Hospital Corporation AGONISTIC ANTI-TUMOR NECROSIS RECEPTOR 2 ANTIBODIES
AU2016332725A1 (en) 2015-09-29 2018-03-22 Celgene Corporation PD-1 binding proteins and methods of use thereof
EP3374399A1 (en) 2015-11-11 2018-09-19 Opi Vi- IP Holdco LLC Composition and methods for anti-tnfr2 antibodies
BR112018010172A2 (pt) 2015-11-19 2018-11-21 Bristol Myers Squibb Co anticorpos contra receptor de fator de necrose de tumor induzido por glicocorticoide (gitr) e usos dos mesmos
EP3383430A4 (en) 2015-12-02 2019-12-18 Agenus Inc. ANTIBODIES AND METHOD FOR USE THEREOF
JP7227007B2 (ja) 2015-12-02 2023-02-21 ストサイエンシス， インコーポレイテッド グリコシル化ｂｔｌａ（ｂ－及びｔ－リンパ球減弱因子）に特異的な抗体
EP3448412A4 (en) * 2016-04-15 2020-03-25 Immunext Inc. ANTI-HUMAN-VISTA ANTIBODIES AND USE THEREOF
CN116715767A (zh) 2016-05-13 2023-09-08 综合医院公司 拮抗性抗肿瘤坏死因子受体超家族抗体
BR112018073739A2 (pt) 2016-05-20 2019-02-26 Harpoon Therapeutics, Inc. proteína de ligação de albumina sérica de domínio único
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
JP2019534859A (ja) 2016-09-19 2019-12-05 セルジーン コーポレイション Ｐｄ−１結合タンパク質を使用して白斑を治療する方法
US10751414B2 (en) 2016-09-19 2020-08-25 Celgene Corporation Methods of treating psoriasis using PD-1 binding antibodies
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
EP3666794A1 (en) 2016-11-01 2020-06-17 AnaptysBio, Inc. Antibodies directed against programmed death- 1 (pd-1)
MA46770A (fr) 2016-11-09 2019-09-18 Agenus Inc Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
CN110382545A (zh) 2017-01-09 2019-10-25 泰萨罗公司 用抗pd-1抗体治疗癌症的方法
US11535668B2 (en) * 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
CA3063359A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Mesothelin binding proteins
GB201712032D0 (en) * 2017-07-26 2017-09-06 Bioinvent Int Ab Antibodies and uses thereof
UA128472C2 (uk) 2017-08-25 2024-07-24 Файв Прайм Терапеутікс Інк. B7-h4 антитіла і методи їх використання
IL272770B2 (en) * 2017-09-19 2025-08-01 Mab Discovery Gmbh Agonistic cd40 antibodies
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
UA129446C2 (uk) 2017-10-13 2025-04-30 Гарпун Терап'Ютікс, Інк. Триспецифічні білки і способи їх застосування
KR102813744B1 (ko) 2017-12-27 2025-05-28 브리스톨-마이어스 스큅 컴퍼니 항-cd40 항체 및 그의 용도
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
BR112020016986A2 (pt) 2018-02-21 2021-03-02 Five Prime Therapeutics, Inc. formulações de anticorpo contra b7-h4
CA3091801A1 (en) 2018-03-02 2019-09-06 Five Prime Therapeutics, Inc. B7-h4 antibodies and methods of use thereof
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
AU2019297451A1 (en) 2018-07-03 2021-01-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
CN118994395A (zh) 2018-07-20 2024-11-22 皮埃尔法布雷医药公司 Vista受体
US20210340268A1 (en) * 2018-08-20 2021-11-04 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
EP3856771A4 (en) 2018-09-25 2022-06-29 Harpoon Therapeutics, Inc. Dll3 binding proteins and methods of use
CN113039201A (zh) * 2018-09-28 2021-06-25 礼进生物医药科技（上海）有限公司 具有经过工程化的Fc结构域的抗CD137结合分子及其治疗用途
WO2020102739A1 (en) * 2018-11-15 2020-05-22 The General Hospital Corporation Agonistic tumor necrosis factor receptor superfamily polypeptides
GB201820547D0 (en) * 2018-12-17 2019-01-30 Oxford Univ Innovation Modified antibodies
CN119661722A (zh) 2019-02-21 2025-03-21 马伦戈治疗公司 结合t细胞相关癌细胞的多功能分子及其用途
EP3927747A1 (en) 2019-02-21 2021-12-29 Marengo Therapeutics, Inc. Antibody molecules that bind to nkp30 and uses thereof
CN112592404B (zh) * 2019-09-20 2023-07-25 上海交通大学医学院 抗体活性改造及其筛选方法
CN113416258B (zh) * 2019-10-24 2023-08-29 北京免疫方舟医药科技有限公司 一种多特异性抗体及其制备方法和用途
GB2609554B (en) 2020-01-03 2025-08-20 Marengo Therapeutics Inc Anti-TCR antibody molecules and uses thereof
WO2021183428A1 (en) 2020-03-09 2021-09-16 Bristol-Myers Squibb Company Antibodies to cd40 with enhanced agonist activity
WO2022159675A2 (en) * 2021-01-21 2022-07-28 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
HRP20250696T1 (hr) 2021-01-28 2025-08-01 Regeneron Pharmaceuticals, Inc. Sastavi i postupci za liječenje sindroma oslobađanja citokina
WO2024121380A1 (en) 2022-12-08 2024-06-13 Pierre Fabre Medicament Vaccinal composition and adjuvant
EP4560319A1 (en) 2023-11-24 2025-05-28 Pierre Fabre Medicament Immune and tumour cells expression of vista in a panel of cancer indications
US20250277048A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration
WO2025184567A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1707627A1 (en) * 2003-12-25 2006-10-04 Kirin Beer Kabushiki Kaisha Mutants of anti-cd40 antibody

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
WO1994021293A1 (en) 1993-03-19 1994-09-29 Duke University Method of treatment of tumors with an antibody binding to tenascin
ATE306930T1 (de) 1994-08-12 2005-11-15 Immunomedics Inc Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper
WO2005007809A2 (en) * 2003-05-30 2005-01-27 Alexion Pharmaceuticals, Inc. Antibodies and fusion proteins that include engineered constant regions
AU2006204459B2 (en) * 2005-01-05 2012-11-01 F-Star Therapeutics Limited Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
US8716451B2 (en) * 2005-01-12 2014-05-06 Kyowa Hakko Kirin Co., Ltd Stabilized human IgG2 and IgG3 antibodies
US7585960B2 (en) 2005-05-11 2009-09-08 Theramab Gmbh Nucleic acids encoding superagonistic anti-CD28 antibodies
MX2008007140A (es) 2005-12-09 2009-03-04 Seattle Genetics Inc Metodos para utilizar agentes de union a cd40.
BRPI0811857A2 (pt) * 2007-05-14 2014-10-21 Biogen Idec Inc Regiões fc (scfc) de cadeia simples, polipeptídeos de aglutinação que as compreendem e métodos relacionados.
AR074438A1 (es) * 2008-12-02 2011-01-19 Pf Medicament Proceso para la modulacion de la actividad antagonista de un anticuerpo monoclonal
JP5694921B2 (ja) * 2009-04-20 2015-04-01 協和発酵キリン株式会社 アミノ酸変異が導入されたＩｇＧ２を有する抗体
JP5469390B2 (ja) * 2009-07-15 2014-04-16 日立コンシューマエレクトロニクス株式会社 再生信号評価方法及び記録調整方法
TW201134488A (en) * 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
KR102049991B1 (ko) 2013-03-28 2019-12-02 삼성전자주식회사 항 c-Met/항 Her2 이중 특이 항체

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1707627A1 (en) * 2003-12-25 2006-10-04 Kirin Beer Kabushiki Kaisha Mutants of anti-cd40 antibody

Also Published As

Publication number Publication date
EP3122779A1 (en) 2017-02-01
EP3590967A1 (en) 2020-01-08
AU2015237864A1 (en) 2016-10-13
US11059898B2 (en) 2021-07-13
JP6682498B2 (ja) 2020-04-15
JP2017511379A (ja) 2017-04-20
WO2015145360A1 (en) 2015-10-01
US20210347907A1 (en) 2021-11-11
US20170158771A1 (en) 2017-06-08
CN107172880B (zh) 2021-09-28
CN107172880A (zh) 2017-09-15
JP2020037577A (ja) 2020-03-12
EP3122779B1 (en) 2019-05-22
CN113912723A (zh) 2022-01-11
CA2943167A1 (en) 2015-10-01

Similar Documents

Publication Publication Date Title
US20210347907A1 (en) Modified antibodies containing modified igg2 domains which elicit agonist or antagonistic properties and use thereof
US20240018238A1 (en) Anti-human vista antibodies and use thereof
US10196450B2 (en) Anti-OX40 antibodies and methods of using the same
WO2017181109A1 (en) Anti-human vista antibodies and use thereof
WO2018144514A2 (en) Tnf superfamily fusion polypeptides
WO2025120015A1 (en) Cd5 targeting antibodies with depleting and t or b-cell activation effects
NZ786412A (en) Anti-human vista antibodies and use thereof

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: CANCER RESEARCH TECHNOLOGY LIMITED

Free format text: FORMER APPLICANT(S): UNIVERSITY OF SOUTHAMPTON

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired